In our previous study, we compared the incidence of hypoglycemia in newly diagnosed T2DM patients receiving combination treatment with continuous subcutaneous insulin injection and DPP-4 inhibitors or AGIs; two weeks of dynamic blood glucose monitoring showed that both therapies have excellent safety 12. This evidence concerns the gene INS and Hypoglycemia.